- Bay Area Times
- Posts
- OpenAI releases o3, o4-mini models, similar quality to Deep Research but faster
OpenAI releases o3, o4-mini models, similar quality to Deep Research but faster
Bay Area Times
April 17, 2025
Brought to you by:
Top stories today:
- OpenAI releases o3, o4-mini, with similar quality to Deep Research
- Together AI brings Open Deep Research to generate images, podcasts
- Trump admin pushes IRS to revoke Harvardâs tax-exempt status
- Retail sales +1.4% in Mar., strongest in 2+ years on car, electronics
- Xi urges âAsian familyâ unity as Trump seeks to confine China
0. Data and calendar
All values as of 6 AM ET / 3 AM PT, other than S&P500 and NASDAQ close (4 PM ET / 1 PM PT).
All times are ET.
Listen to our AI-generated podcast summarizing todayâs newsletter (beware of hallucinations):
1. OpenAI releases o3, o4-mini models, similar quality to Deep Research but faster
o3 has outperformed Googleâs Gemini 2.5 Pro, while o4-mini-high surpassed Claude 3.7 Sonnet on the coding-focused Aider benchmark:
o3, o4-mini, and o4-mini-high use all ChatGPT tools, including web browsing, Python code execution, and image analysis.
Can âthink with imagesâ by integrating uploaded visuals into their âchain-of-thoughtâ.
Restrict biological and chemical threat prompts through a new safeguard.
Available to ChatGPT Pro, Plus, Team subscribers.
Chat Completion API and Responses API also provide access to the new models.
o3 costs $10/M input and $40/M output tokens, vs. o1 at $15/M and $60/M.
o4-mini costs $1.10/M input and $4.40/M output tokens, the same as o3-mini.
o3 is seen completing complex research in 30s-5min., vs. 5-30min. with the regular Deep Research
o3 has topped Humanityâs Last Exam
o3-pro will also be released âin a few weeksâ for the ChatGPT Pro users.
Over 365 million people worldwide suffer from osteoarthritis and there's still no cure, just painkillers and ice packs.
Cytonicsâ CYT-108 is a lab-tweaked version of a natural protein (A2M) that blocks the enzymes that eat away at cartilage.
Backed by NIH grants and over 6,000 shareholders, Cytonics is now letting the public invest in its next clinical trial phase.
Itâs a shot at finally treating the root cause of joint pain, not just managing it.
*Sponsored by Cytonics ($50,000 contracted). Prospective investors should review the offering materials for details, including all risk factors, before making an investment decision. Any investment involves significant risks, including the potential loss of the total investment. This advertisement is not an offer to sell or a solicitation of an offer to buy securities. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please read the offering circular before investing in Cytonics.
3. Together AI brings open-source Deep Research that can generate images, podcasts
Based on a human-like research workflow, which includes planning and self-reflection components:
